



**Global Vaccine and Immunization Research Forum (GVIRF)  
4 to 6 March 2014  
Hyatt Regency Bethesda, USA**

**AGENDA**

<b>TUESDAY 4 MARCH 2014    Crystal Ballroom</b>		
07:30-08:30	Registration ( <i>Crystal Ballroom Foyer</i> )	
08:30-08:45	Welcome and Opening remarks	F. Becerra J.-M. Okwo Bele
08:45-09:15	Key note lecture <i>Vaccine Research and Development: Challenges and Opportunities</i>	A. Fauci
09:15-09:25	GVIRF in the context of the Decade of Vaccines	L. Hall
09:25-09:35	GVIRF overview and link to the Global Vaccine Action Plan	J. Hombach
09:35-09:45	What do we expect from the meeting?	J. Esparza
	<b>Plenary 1: Develop New and Improved Vaccines</b>	<b>Chair: C. Mgone</b>
09:45-10:05	Progress towards the development of an HIV vaccine	W. Koff
10:05-10:15	Discussion	J. Esparza
10:05-10:15	Progress towards the development of a TB vaccine	T. Evans
10:15-10:25	Discussion	U. Fruth
10:25-10:35	Progress towards the development of a malaria vaccine	A. Birkett
10:35-10:45	Discussion	P. Smith

10:45 - 11:10	<i>Coffee break Crystal Ballroom Foyer</i>	
	<b>Plenary 2: Regulatory and Public Health Challenges for Vaccines Inducing Modest Efficacy</b>	<b>Chair: D. Salisbury</b>
11:10-11:05	Introduction	D. Salisbury
11:05-11:15	Regulatory and public health challenges	P. Smith
11:15-11:45	Panel Discussion Panellists: M. Gruber, P. Neels, P. Smith, B. Gessner	
11:45-12:00	Summary remarks	D. Salisbury
12:00-12:10	Introduction of workshops	J. Esparza
12:10 – 13:30	<i>Lunch Concours Terrace</i>	
	<b>Workshop 1: Towards the Development of a Universal Influenza Vaccine</b> <b>Venue: Cabinet/Judiciary</b>	<b>Chair: D. Spiro</b>
13:30-13:45	Introduction to the workshop and summary of key findings from narrative report	D. Spiro
13:45-15:00	Introduction to the workshop followed by panel discussion Panellists: R. Donis, R. Rappuoli, G. Nabel, N. Baylor, P. Palese, H. Golding	
	Summary remarks	D. Spiro

	<p><b>Workshop 2: Preferred Product Characteristics (PPC) as a Way to Guide Development of Products of High Public Health Utility</b>  <b>Venue: Old Georgetown</b></p>	<p><b>Chair: G. Zettlmeissl</b></p>
13:30-13:45	Introduction	G. Zettlmeissl
13:45-14:00	Presentation of the PPC concept	V. Moorthy
	Case study: Key obstacles to RSV vaccine development for low and middle income countries Case study: Key obstacles to Group A Streptococcus vaccine development for low and middle income countries	C. Lanata F. Schodel
14:55-15:00	Discussion: How can a WHO PPC help the development of vaccines for low and middle income countries? Panellists: C. Lanata, F. Schodel, D. Kaslow, R. Lagos	
	Summary remarks	G. Zettlmeissl

<b>Workshop 3: Vaccines Against Neglected Infectious Diseases</b> <b>Venue: Crystal Ballroom</b>		<b>Chair: O. Leroy</b>
13:30-13:35	Introduction	O. Leroy
13:35-13:45	Case study: Leishmania vaccine development: Progress and challenges in the context of other control strategies	F. Modabber
13:45-14:15	Discussion Panelists: S. Sundar, D. Sacks, R. Fujiwara, L. Gordon, P. Hotez	
14:15-14:25	Pre-exposure rabies vaccination in children of endemic countries	D. Briggs
14:25-14:55	Discussion Panellists: L. Blumberg, D. Briggs, R. Lopez Ingunza, R. Deray	
14:55-15:00	Concluding remarks	O. Leroy
<b>15:00 – 15:30</b>	<b><i>Coffee break Crystal Ballroom Foyer</i></b>	

15:30-16:00	Plenary reporting of the workshops' conclusions	D. Spiro, G. Zettlmseisl, O. Leroy
16:00-16:30	Discussion	
<b>Plenary 3: Developing Next Generation Vaccines: Defining the Improvements Needed and Evaluating Their Potential</b>		<b>Chair: K. Neuzil</b>
16:30-16:35	Introduction	K. Neuzil
16:35-16:45	Current rotavirus vaccines: achievements and limitations	U. Parashar
16:45-16:55	Prospects from pipeline vaccines to address remaining public health needs	M. Estes
16-45-17:05	Evaluation of the next generation vaccines	K. Neuzil
16:55-17:25	Discussion Panellists: D. Steele, U. Parashar, M. Estes, G. Kang	
17:25-17:30	Summary remarks	K. Neuzil
<b>17:30</b>	<b>Adjourn</b>	
<b>18:00-19:00</b>	<b>Reception Concours Terrace</b>	

<b>Wednesday 5 MARCH 2014      Crystal Ballroom</b>		
	<b>Plenary 4: Research for Universal Coverage and Immunization in the Post- MDG Poverty Reduction Agenda</b>	<b>Chair: S. Sow</b>
08:45-09:15	Keynote Lecture: <i>Research for Universal Health Coverage</i>	M. Chan
09:15-09:45	Perspective on vaccine and poverty reduction	T. Evans
09:45-10:00	Introduction of the panel workshops	L. Hall
<b>10:00- 10:30</b>	<b>Coffee break   Crystal Ballroom Foyer</b>	
	<b>Workshop 4: How to Optimize Immunization Coverage? – A Case Study from Measles-Rubella Vaccination</b> <b>Venue: Old Georgetown</b>	<b>Chair: D. Durrheim</b>
10:30-10:35	Introduction	D. Durrheim
10:35-10:45	Progress, challenges and lessons learned in achieving measles/rubella goals	T. Cherian
10:45-10:55	Proposed measles/rubella implementation and technical research agenda	W. Moss
10:55-12:00	Discussion Panellists: T. Cherian, W. Moss, W. Orenstein, H. Rees	

	<b>Workshop 5: Research Capacity Strengthening to Foster Implementation Research in Developing Countries</b> <b>Venue: Cabinet/Judiciary</b>	<b>Chair: J. Reeder</b>
10:30-10:35	Introduction	J. Reeder
10:35-10:50	WHO implementation research agenda setting in conjunction with the Global Vaccine Action Plan objectives	J. Clemens
10:50-11:00	Research capacity strengthening in low income countries: what works and what doesn't work	
11:00-11:15	<ul style="list-style-type: none"> <li>• Case study I: Factors influencing volunteers participating in health programmes in Africa</li> </ul>	F.Y. Bocoum
11:15-11:30	<ul style="list-style-type: none"> <li>• Case study II: Assessing the cost of immunization programmes in Latin America</li> </ul>	C. Janusz
11:30-11:55	<ul style="list-style-type: none"> <li>• Case study III: Strengthening capacity for immunization research in Africa</li> </ul>	O. Okeibunor on behalf of M. Gyapong
	Discussion Panellists: F.Y. Bocoum, C. Janusz, J. Okeibunor; J Clemens	J. Reeder
11:55-12:00	Summary remarks	

	<p><b>Workshop 6: Innovation in vaccine delivery and presentation: How can Technological Advances Increase Program Performance</b>  <b>Venue: Crystal Ballroom</b></p>	<p><b>Co-Chairs: R. Lagos, M. Gottlieb</b></p>
10:30-10:35	Introduction	R. Lagos, M. Gottlieb
10:35-10:50	Conclusions from a WHO vaccine delivery technologies workshop	D. Zehrung
10:50-11:00	Meningococcal A vaccine and controlled temperature chain (CTC) in Benin	O. Ronveaux
11:00-11:10	Uniject delivery device	D. Kristensen
11:10-11:55	Discussion Panellists: D. Kristensen, P. Heaton, O. Popova, O. Ronveaux	
11:55-12:00	Summary remarks	R. Lagos, M. Gottlieb
<b>12:00 - 13:30</b>	<b>Lunch break    <i>Concours Terrace</i></b>	
13:30-14:00	Reporting of the workshops conclusions	D. Durrheim, J. Reeder, R. Lagos/M. Gottlieb
14:00-14:30	Discussion	



	<b>Plenary 5: Research to Improve Monitoring and Evaluation of Immunization Programmes</b>	<b>Chair: J.M. Okwo-Bele</b>
14:30-14:45	Introduction (outline of the concept, landscape, progress and future directions)	C. Danovaro
14:45-15:00	Case study: REVELAC-I case control studies	A.M. Ropero Alvarez
15:00-15:30	Discussion: Research needs in relation to feasibility, impact and use of data for policy making	J.M. Okwo-Bele
<b>15:30 - 16:00</b>	<b><i>Coffee break Crystal Ballroom Foyer</i></b>	
	<b>Plenary 6: Protection of Pregnant Women, Neonates and Infants by Maternal Immunization</b>	<b>Chair: H. Rees</b>
16:00-16:10	Introduction (objectives and expected outcomes)	H.Rees
16:10-16:25	Public health benefits of maternal immunization	K. Klugman
16:25-16:40	Immunological considerations: Impact of maternal immunization on infant immunity	C.A. Siegrist
16:40-17:30	Discussion Panellists: C.A. Siegrist, K. Klugman, A. Precioso, J. Englund, S. Madhi, K. Jansen P. Neels, M. Wharton	
<b>17:30</b>	<b><i>Adjourn</i></b>	

<b>Thursday 6 MARCH 2014 Crystal Ballroom</b>		
08:30-09:00	Keynote Lecture: <i>The importance of innovation in addressing global health gaps in the developing world</i>	T. Mundel
	<b>Plenary 7: Innovative Vaccine Research: the Point of View of Industry and Biotech Companies</b>	<b>Co-Chairs: M. Mowatt, O. Leroy</b>
09:00-09:20	Intellectual property, innovation and the need for a new business model	M. Friede
09:20-10:00	Discussion Panellists: S. Jadhav, M. Watson, S. Singh, K. Kelley, M. Friede, E. Hanon, J. van Hoof, M. McGlynn, G. van Roekel	
10:00-10:10	Introduction of the panel workshops	J. Hombach
<b>10:10 - 10:40</b>	<b>Coffee break Concours Terrace</b>	
	<b>Workshop 7: Contributions of Regulatory Science to Vaccine Access</b> <b>Venue: Cabinet/Judiciary</b>	<b>Co-Chairs: N. Baylor, H. Rees</b>
10:40-10:50	Introduction	N. Baylor
10:50-11:00	Case study I: Enhancements in laboratory research to support innovations in regulatory science for the evaluation of new vaccines	T. Jivapaisarnpong
11:00-11:10	Case study II: How can innovation in regulatory science inform the regulatory process to facilitate the development of new vaccines	M. Gruber
11:10-11:55	Discussion Panellists: M. Gruber, T. Jivapaisarnpong	
11:55-12:00	Summary Remarks	N. Baylor, H. Rees

	<p><b>Workshop 8: How can Recent Technological Advances in Vaccinomics and Systems Vaccinology Accelerate Next-Generation Vaccine Development?</b>  <b>Venue: Crystal Ballroom</b></p>	<p><b>Chair:</b>  <b>I. Jonsdottir</b></p>
10:40-10:45	Introduction	I. Jonsdottir
10:45-10:55	Systems vaccinology for the evaluation of vaccine response and identification of critical pathways	B. Pulendran
10:55-11:05	Application of technological advances to clinical trials	W. Hanekom
11:05-12:05	Discussion Panellists: B. Pulendran, W. Hanekom, D. Lewis, E. Hanon, P. Neels	
12:05-12:10	Summary remarks	I. Jonsdottir
<b>12:10 - 12:25</b>	<b><i>Reconvene in the Crystal Ballroom</i></b>	
12:25-13:05	Plenary reporting of the workshops conclusions	N. Baylor, I. Jonsdottir
13:05-13:30	General conclusion Closing address	L. Hall, C. Wilson, J.M. Okwo-Bele